Fidelity Investments
UROV

Fidelity Investments’s Urovant Sciences Ltd. UROV Stock Holding History

Fidelity Investments’s Portfolio UROV Stock Details UROV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-568,436
Closed -$5.31M – 4457
2020
Q3 		$5.31M Sell
568,436
-144,300
-20% -$1.28M ﹤0.01% 2056
2020
Q2 		$7.01M Sell
712,736
-180,800
-20% -$1.73M ﹤0.01% 1940
2020
Q1 		$8.24M Sell
893,536
-163,400
-15% -$1.97M ﹤0.01% 1756
2019
Q4 		$16.4M Sell
1,056,936
-653,900
-38% -$7.09M ﹤0.01% 1670
2019
Q3 		$16.2M Hold
1,710,836
– – ﹤0.01% 1650
2019
Q2 		$13.5M Hold
1,710,836
– – ﹤0.01% 1774
2019
Q1 		$17.2M Buy
1,710,836
+378,135
+28% +$3.88M ﹤0.01% 1662
2018
Q4 		$8.78M Buy
1,332,701
+132,701
+11% +$1.21M ﹤0.01% 1844
2018
Q3 		$14.4M Buy
+1,200,000
New +$14.2M ﹤0.01% 1819

Other funds holding UROV

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
OCM
Orchard Capital Management Chicago, Illinois $95.9M AUM 45.49% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

Fidelity Investments's UROV Position: Q4 2020 in Review

Fidelity Investments sold out of Urovant Sciences Ltd. (UROV) in Q4 2020, closing a stake of 568,436 shares — an estimated $5.31M sold.

Fidelity Investments first reported a position in UROV in Q3 2018 and held it in 9 quarters. The position peaked at $17.2M in Q1 2019. 41 funds tracked by Wall St. Rank hold UROV as of Q4 2020.

  • Fidelity Investments reported no remaining Urovant Sciences Ltd. position as of Q4 2020 after selling out during the quarter.
  • Fidelity Investments sold 568,436 Urovant Sciences Ltd. shares in Q4 2020, an estimated $5.31M.
  • Fidelity Investments first reported a position in Urovant Sciences Ltd. in Q3 2018 and held it in 9 quarters.
  • Fidelity Investments's Urovant Sciences Ltd. position peaked at $17.2M in Q1 2019.
  • 41 funds tracked by Wall St. Rank held Urovant Sciences Ltd. as of Q4 2020.

Based on Fidelity Investments's 13F filing for Q4 2020, filed 8 Feb 2021.